T2-high asthma

This study tested whether switching to a new drug called depemokimab (GSK3511294) works as well as staying on current treatments (mepolizumab or benralizumab) for people with severe asthma linked to high eosinophils. Over 1,700 adults and teens took part for 52 weeks, continuing …

This study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control severe asthma. Researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearabl…

This study looked at 43 adults in Taiwan with severe eosinophilic asthma who were already prescribed benralizumab. Researchers tracked changes in asthma control using a standard questionnaire over time. The goal was to see how well the drug works in everyday medical practice, not…

This study looked at how well benralizumab (Fasenra) works for people with severe eosinophilic asthma in real-world clinics across the Gulf, Latin America, and India. Researchers tracked 291 patients to see if their asthma control improved over time using a standard questionnaire…

This completed study looked at the safety and effectiveness of FASENRA (benralizumab) in 51 Korean adults with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA). Researchers tracked side effects and how well the drug controlled symptoms during rou…

This study followed 106 adults with severe eosinophilic asthma in Poland who received mepolizumab injections every 4 weeks for at least a year. Researchers tracked asthma attacks and the need for oral steroids before and during treatment. The goal was to see if the drug helps con…

This study looked at the long-term safety of a drug called depemokimab in 641 adults and teenagers with severe asthma caused by a type of white blood cell called eosinophils. Participants had already completed earlier studies and received the drug for another 12 months. The main …

This study tested an experimental nasal spray called AD17002 in 40 adults with poorly controlled moderate-to-severe eosinophilic asthma. Participants self-administered the spray twice a week for six weeks. The goal was to see if it could improve lung function and reduce the need …

This study looked at whether giving a low dose of a muscle relaxant (rocuronium) during bronchoscopy—a procedure where a tube is inserted into the lungs—could reduce complications like throat spasms and coughing. 153 adults having elective bronchoscopy were split into two groups:…

This study tested whether a CT scan of the lungs could predict which patients with severe eosinophilic asthma would respond well to the drug benralizumab. 59 adults received benralizumab for 48 weeks and had CT scans at the start, middle, and end of treatment. The goal was to see…

This study looked at different types of immune cells (eosinophils) in the blood of people with asthma, chronic sinusitis with nasal polyps, or both, compared to healthy volunteers. The goal was to find patterns that could help doctors choose the best targeted therapy for each pat…

This study looked at how the asthma drug mepolizumab affects gene activity in adults with severe eosinophilic asthma. Researchers took blood samples from 20 participants before and after 12 weeks of treatment to see which genes changed. The goal was to understand how the drug wor…

This study looked at how mepolizumab, a biologic drug, changes inflammation in people with severe eosinophilic asthma. Researchers measured immune and metabolic markers in the nose, lungs, and blood of 15 adults. The goal was to better understand the drug's full impact beyond jus…

This completed study looked back at medical records of 74 adults in Portugal with severe eosinophilic asthma who were treated with benralizumab. Researchers wanted to describe patient characteristics, treatment patterns, and outcomes in real-world settings. The study did not test…